Home Editor's Picks Life Beyond GLP-1s: Piper Sandler’s top stock picks amid shifting biotech landscape

Life Beyond GLP-1s: Piper Sandler’s top stock picks amid shifting biotech landscape


Life Beyond GLP-1s: Piper Sandler’s top stock picks amid shifting biotech landscape By Investing.com

Breaking News


AuthorVahid KaraahmetovicPro News

Published Mar 08, 2024 08:32AM ET

© Reuters. Life Beyond GLP-1s: Piper Sandler’s top stock picks amid shifting biotech landscape

Dive into the world of savvy investing with InvestingPro! We’re giving you this eye-opening article for FREE, showcasing pro-level insights in real-time. Seize the opportunity and upgrade today with promo code HOT2024 for an additional 10% off already discounted rates (save up to 50%). Time is ticking – upgrade now with just a click.


In a Friday note to clients, Piper Sandler analysts focused on “life beyond GLP-1s,” short for Glucagon-like Peptide-1 agonists – a class of medications primarily used in the treatment of type 2 diabetes and obesity.

These treatments are at the early stages of what many believe will be a significant growth trajectory.

However, there’s growing apprehension that GPL-1s, despite reliably promoting a 15-20% weight reduction within a year, may lead to a considerable loss of lean muscle mass—about 20-40% of the total weight lost, Piper Sandler pointed out in its note.

In addition, emerging evidence suggests that weight tends to be rapidly regained once treatment ceases. In response to these concerns, the industry is increasingly turning towards a polypharmacy approach, aiming to address both weight loss and the preservation of lean muscle.

“While some have debated that this can be addressed by exercise and diet, we think a pharmacological approach would address this emerging unmet need as well,” analysts wrote.

Against this backdrop, the analysts highlighted Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN), Regeneron Pharmaceuticals (NASDAQ:REGN), and Scholar Rock Holding (NASDAQ:SRRK) among the few companies focused on this emerging unmet need.

Their approaches generally target the signaling of key regulators of muscle growth: myostatin and activin, Piper Sandler explained.

“On our lists, BHVN’s T-alfa binds mature myostatin and prevents ActRIIB receptor binding, REGN is developing two antibodies targeting activin A and myostatin, respectively, and SRRK is developing an antibody that binds pro- and latent myostatin.”

The broker holds an Overweight rating on this trio.

Meanwhile, Eli Lilly and Company (NYSE:LLY), one of the frontrunners in the ongoing weight-loss drug revolution, is also on this list, with anticipated phase 2b data for bimagrumab expected around mid-2024.

Moreover, Roche (SIX:ROG) and Keros Therapeutics Inc (NASDAQ:KROS) are advancing their respective programs in this space, which are also being monitored.

Upgrade your investing today and save big with promo code HOT2024

Life Beyond GLP-1s: Piper Sandler’s top stock picks amid shifting biotech landscape

Our Apps

Terms And Conditions
Privacy Policy
Risk Warning
Do not sell my personal information

© 2007-2024 Fusion Media Limited. All Rights Reserved.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Related News